-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, immune checkpoint blocking therapy has shown success in the treatment of many types of tumors, but it has been helpless against pancreatic cancer, which is known as the "king of cancer
For a long time, immune checkpoint blocking therapy based on programmed death receptors and their ligands has not worked against pancreatic cancer
Through a variety of sequencing and screening, the research team found that osteopontin and its ligands are another immune checkpoint besides the programmed death receptor and its ligands, which promote the development of pancreatic cancer by compensating for the function of the programmed death receptor.
Studies have found that the inhibitor WDR5-47 can effectively inhibit the expression of osteopontin in pancreatic tumor cells and myeloid-derived suppressor cells, and has great potential to be developed as an immunotherapy monotherapy for the treatment of pancreatic cancer